Immunovant, Inc. — Form 10-Q Summary
Reporting period: Fiscal quarter and nine months ended December 31, 2023; fiscal year ends March 31. Financial statements are unaudited and presented under U.S. GAAP.
Business context
Immunovant is a clinical-stage biopharmaceutical company developing batoclimab and IMVT-1402, fully human monoclonal antibodies targeting FcRn for IgG-mediated autoimmune diseases. The company has no approved products and has generated no product revenue. Its principal programs address myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves’ disease.
Financial performance and position
| Metric | Three months ended Dec. 31, 2023 | Three months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2023 | Nine months ended Dec. 31, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $48.3 million | $42.3 million | $146.9 million | $108.4 million |
| Acquired in-process R&D | $0 | $10.0 million | $12.5 million | $10.0 million |
| General and administrative | $13.2 million | $11.8 million | $42.5 million | $35.6 million |
| Total operating expenses | $61.6 million | $64.0 million | $201.8 million | $154.0 million |
| Net loss | $51.4 million | $63.2 million | $184.0 million | $151.5 million |
| Basic and diluted loss per share | $0.36 | $0.49 | $1.36 | $1.26 |
Interest income was $8.9 million in the quarter and $16.6 million for the nine months, reflecting the larger cash balance. Other income, net, was $1.1 million in the quarter and $1.6 million for the nine months. Operating and net margins are not meaningful because the company has no revenue and remains loss-making.
- Cash and cash equivalents: $690.9 million at December 31, 2023, compared with $376.5 million at March 31, 2023.
- Operating cash use: $154.5 million for the nine months, compared with $132.4 million in the prior-year period.
- Financing cash flow: $470.9 million, primarily from the October 2023 equity offering and private placement; net proceeds were approximately $466.7 million.
- Accumulated deficit: $750.4 million at December 31, 2023.
- Debt: The filing does not report outstanding debt. Total liabilities were $32.1 million, primarily accounts payable, accrued expenses and current operating lease liabilities.
- Equity: 145.1 million common shares were outstanding at December 31, 2023; 145.3 million were outstanding as of February 5, 2024.
Material changes versus the prior comparable period
- Quarterly R&D expense increased $6.1 million, primarily from higher IMVT-1402 spending and personnel-related costs, partially offset by lower batoclimab endocrine-program costs.
- Nine-month R&D expense increased $38.5 million. IMVT-1402 program costs increased by $22.6 million, while personnel-related R&D costs increased by $15.7 million.
- Nine-month total operating expenses increased $47.8 million, including a $2.5 million increase in acquired in-process R&D expense from HanAll milestones.
- Quarterly net loss improved by $11.8 million because the prior-year quarter included a $10.0 million HanAll milestone expense and the company earned substantially more interest income.
- Nine-month net loss increased $32.5 million because of higher clinical development, personnel and milestone costs.
- October 2023 financing increased cash by approximately $314.4 million during the first nine months after considering operating, investing and financing activity.
- Shares outstanding increased materially following the issuance of 12.95 million shares in the public offering and private placement, resulting in dilution to existing holders.
Clinical progress, outlook and unusual items
- In the IMVT-1402 Phase 1 trial, four weekly 600 mg doses produced a reported 74% reduction from baseline in mean total IgG. The company reported no or minimal albumin reductions and no or minimal LDL increases, with changes consistent with placebo. Treatment-emergent adverse events were generally mild or moderate.
- In an initial Graves’ disease Phase 2 cohort, 680 mg batoclimab produced mean IgG reduction of 81% after 12 weeks, with reductions up to 87%. The trial remains ongoing and the data are preliminary.
- Management expects initial open-label data from the CIDP Phase 2b trial in the second or third quarter of calendar 2024, top-line MG Phase 3 data in the second half of calendar 2024 and top-line TED Phase 3 data in the first half of calendar 2025.
- Management plans to initiate four to five potentially registrational IMVT-1402 programs by March 31, 2025 and trials in ten indications by March 31, 2026.
- The company expects R&D expenses and operating losses to continue increasing as it advances clinical programs, expands manufacturing and prepares for potential regulatory submissions.
- Management states that December 31, 2023 cash is expected to fund operating expenses and capital expenditures for at least the next 12 months, but also states that current funds will not be sufficient to complete all development and potential commercialization activities.
- The company has an ATM program permitting sales of up to $150.0 million of common stock; no shares had been sold under the program as of the filing.
Commitments, contingencies and principal risks
- Under the HanAll Agreement, potential future milestone payments total up to $420.0 million after $32.5 million of milestones achieved through December 31, 2023. Tiered royalties ranging from the mid-single digits to mid-teens percentage of net sales would apply if products are commercialized.
- The company has a remaining Samsung manufacturing commitment of approximately $18.3 million and an additional approximately $28.0 million obligation for batches scheduled for 2026 through 2029 after allowing its early termination right to lapse.
- A putative securities class action related to historical batoclimab safety disclosures remains pending. The company has not accrued a liability because it cannot reasonably estimate potential losses or determine whether an unfavorable outcome is probable.
- Key risks include failure of clinical trials, regulatory delays or non-approval, batoclimab lipid and albumin safety concerns, patient enrollment and retention challenges, reliance on CROs and contract manufacturers, competition from other FcRn therapies, dependence on the HanAll license, need for additional capital and potential equity dilution.
- Roivant Sciences Ltd. beneficially owned approximately 54.9% of voting power as of February 5, 2024, giving it substantial control over stockholder and board matters.
- Management concluded that disclosure controls and procedures were effective as of December 31, 2023, with no material change in internal control over financial reporting during the quarter.
Investor verification checklist
- Verify the timing and results of the MG, TED, CIDP and Graves’ disease batoclimab programs and the next IMVT-1402 trial initiations.
- Assess whether preliminary IgG reductions and favorable albumin and LDL observations are replicated in larger, longer-duration patient trials.
- Reconcile projected cash runway with the planned expansion of IMVT-1402 programs, manufacturing obligations and contingent HanAll milestones.
- Monitor future equity issuance, including use of the $150.0 million ATM program and resulting dilution.
- Review the pending securities litigation and any subsequent developments that could create a liability or cash exposure.
- Evaluate manufacturing readiness, Samsung commitments and regulatory acceptance of third-party manufacturing facilities.
- Confirm whether the company obtains regulatory approval and whether competitive FcRn products affect enrollment, pricing or commercial differentiation.